{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:08:54Z","timestamp":1790719734737,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.clinthera.2009.05.014","type":"journal-article","created":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T08:41:52Z","timestamp":1245228112000},"page":"999-1006","source":"Crossref","is-referenced-by-count":12,"title":["Effect of multidrug resistance gene-1 (ABCB1) polymorphisms on the single-dose pharmacokinetics of cloxacillin in healthy adult Chinese men"],"prefix":"10.1016","volume":"31","author":[{"given":"Ophelia Q.P.","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses S.S.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.05.014_bib1","first-page":"347","article-title":"Comparative bioavailability and half-lives of cloxacillin and flucloxacillin","volume":"6","author":"Paton","year":"1986","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1016\/j.clinthera.2009.05.014_bib2","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1248\/cpb.31.3292","article-title":"Comparative pharmacokinetics of metabolism and urinary excretion of isoxazolylpenicillins in man","volume":"31","author":"Murai","year":"1983","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.clinthera.2009.05.014_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2125.1988.tb03280.x","article-title":"Saturation of the tubular excretion of beta-lactam antibiotics","volume":"25","author":"Bins","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2009.05.014_bib4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bmj.4.5733.455","article-title":"Flucloxacillin, a new isox-azolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin","volume":"4","author":"Sutherland","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.clinthera.2009.05.014_bib5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1023\/A:1015191511817","article-title":"Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport?","volume":"19","author":"Susanto","year":"2002","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2009.05.014_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: Transport\/absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2009.05.014_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","article-title":"Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance","volume":"75","author":"Marzolini","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2009.05.014_bib8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2165\/00003088-200443090-00001","article-title":"The MDR1 (ABCB1) gene polymorphism and its clinical implications","volume":"43","author":"Ieiri","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2009.05.014_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/mcp.2001.117412","article-title":"Identification of functionally variant MDR1 alleles among European Americans and African Americans","volume":"70","author":"Kim","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2009.05.014_bib10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00008571-200208000-00004","article-title":"Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations","volume":"2","author":"Tang","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.clinthera.2009.05.014_bib11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00008571-200312000-00005","article-title":"Haplotype analysis of ABCB1\/ MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan","volume":"13","author":"Sai","year":"2003","journal-title":"Pharma-cogenetics"},{"key":"10.1016\/j.clinthera.2009.05.014_bib12","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jps.20717","article-title":"MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells","volume":"95","author":"Salama","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2009.05.014_bib13","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/jps.2600710826","article-title":"High-pressure liquid chromatographic assay of cloxacil-lin in serum and urine","volume":"71","author":"Teare","year":"1982","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2009.05.014_bib14","series-title":"Pharmacokinetics","author":"Gibaldi","year":"1982"},{"key":"10.1016\/j.clinthera.2009.05.014_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00008571-200104000-00005","article-title":"MDR1 pharmacogenetics: Frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity","volume":"11","author":"Ameyaw","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.clinthera.2009.05.014_bib16","series-title":"Basic Statistics and Pharmaceutical Statistical Applications","author":"De Muth","year":"1999"},{"key":"10.1016\/j.clinthera.2009.05.014_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.clpt.6100046","article-title":"Genetic polymorphisms in the ABCB1 gene and the effects of fen-tanyl in Koreans","volume":"81","author":"Park","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2009.05.014_bib18","doi-asserted-by":"crossref","first-page":"18526","DOI":"10.1074\/jbc.272.30.18526","article-title":"Expression cloning and characterization of a novel multispecific organic anion transporter","volume":"272","author":"Sekine","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2009.05.014_bib19","first-page":"F706","article-title":"Recognition of beta-lactam antibiotics by rat peptide transporters PEPT1 and PEPT2, in LLC-PK1 cells","volume":"273","author":"Terada","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.clinthera.2009.05.014_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejpb.2004.07.008","article-title":"Interaction of 31 beta-lactam antibiotics with the H+\/peptide symporter PEPT2: Analysis of affinity constants and comparison with PEPT1","volume":"59","author":"Luckner","year":"2005","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.clinthera.2009.05.014_bib21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1592\/phco.28.7.883","article-title":"Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis","volume":"28","author":"Beringer","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2009.05.014_bib22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1177\/0091270004273492","article-title":"Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharma-cokinetics","volume":"45","author":"Putnam","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2009.05.014_bib23","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1073\/pnas.96.14.7871","article-title":"Single-nucleotide polymorphisms can cause different structural folds of mRNA","volume":"96","author":"Shen","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2009.05.014_bib24","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.1158\/1078-0432.CCR-05-2649","article-title":"Pharmacoge-netic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel","volume":"12","author":"Bosch","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180900160X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180900160X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T00:27:31Z","timestamp":1545179251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929180900160X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S014929180900160X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.05.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}